Atria Investments Inc Has $475,000 Stake in DaVita Inc. (NYSE:DVA)

Atria Investments Inc raised its holdings in shares of DaVita Inc. (NYSE:DVA) by 12.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,897 shares of the company’s stock after purchasing an additional 317 shares during the quarter. Atria Investments Inc’s holdings in DaVita were worth $475,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Blue Trust Inc. raised its position in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after buying an additional 78 shares during the last quarter. Family Firm Inc. purchased a new position in shares of DaVita in the 2nd quarter worth approximately $43,000. Versant Capital Management Inc grew its holdings in shares of DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares in the last quarter. Friedenthal Financial purchased a new stake in shares of DaVita during the second quarter valued at approximately $48,000. Finally, Point72 Hong Kong Ltd bought a new stake in DaVita during the second quarter worth $68,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Truist Financial raised their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Bank of America lifted their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. TD Cowen increased their target price on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, UBS Group increased their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus target price of $161.80.

DaVita Stock Performance

Shares of DVA stock opened at $161.40 on Thursday. The firm’s 50 day moving average is $158.14 and its 200 day moving average is $147.97. The stock has a market capitalization of $13.23 billion, a P/E ratio of 17.41, a PEG ratio of 0.90 and a beta of 0.89. DaVita Inc. has a 12 month low of $97.31 and a 12 month high of $168.50. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the previous year, the business earned $2.85 earnings per share. DaVita’s revenue was up 4.6% on a year-over-year basis. On average, sell-side analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

Insider Activity

In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This represents a 36.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the completion of the sale, the chief executive officer now directly owns 905,659 shares in the company, valued at approximately $141,219,407.87. The trade was a 3.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 156,086 shares of company stock worth $24,807,161 over the last ninety days. Company insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.